Loading...
OTCM
ITNS
Market cap457kUSD
Dec 05, Last price  
0.00USD
1D
0.00%
1Q
0.00%
Jan 2017
-85.71%
IPO
-99.82%
Name

ITonis Inc

Chart & Performance

D1W1MN
OTCM:ITNS chart
P/E
P/S
1,328.56
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
-47.57%
Revenues
0k
-80.90%
024,351206,8284507,6699,1178,6802,4734,4273,0501,801344
Net income
-10k
L-74.87%
-1,118,841-2,302,278-1,398,326-422,703-385,494-71,793-61,022-48,506-71,385-7,573-38,313-9,628
CFO
-112k
L+1,248.28%
-34,543-399,934-584,362-77,681-60,314-84,249-55,352-53,249-38,648-8,293-111,813

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Itonis, Inc., a development stage company, focuses on producing and marketing over the counter and prescription homeopathic preparations to treat common ailments and chronic diseases. The company intends to sells its over-the-counter to alleviate mild to moderate nausea. It has placed a manufacturing order for the first batch of its Emesyl product line. The company was formerly known as Kenshou, Inc. and changed its name to Itonis, Inc. in December 2005. Itonis, Inc. was founded in 2005 and is headquartered in Laguna Hills, California.
IPO date
Feb 21, 2007
Employees
3
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑112023‑112022‑112021‑112020‑112019‑112018‑112017‑112016‑11
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT